ChemoCentryx's avacopan flunks mid-stage study in rare kidney disease study

Dec. 21, 2020 4:46 PM ETAmgen Inc. (AMGN)By: Vandana Singh, SA News Editor5 Comments
  • ChemoCentryx (NASDAQ:CCXI) down 5% after hours on topline data from Phase 2 study, ACCOLADE, evaluating avacopan for the treatment of C3 glomerulopathy (kidneys malfunction leading to excess levels of protein in urine).
  • The trial showed the change from baseline to week 26 in

Recommended For You

Comments (5)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.